• Armata Pharmaceuticals disclosed FDA agreement on an initial pediatric study plan for AP-SA02 in complicated Staphylococcus aureus bacteremia.
• The plan supports a future BLA path, setting a pediatric development framework alongside the adult program.
• Pediatric study deferred until adult Phase 3 safety and efficacy data; adult Phase 3 expected to start in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA02587) on July 13, 2026, and is solely responsible for the information contained therein.